Capricor Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Capricor Therapeutics Inc.
- Former names
- Nile Therapeutics, Inc. SMI Products Inc
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- SAN Diego
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- CAPR
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001133869
Board of directors
-
David B. Musket · DirectorSince 2023
-
Earl M. Collier Jr. · DirectorSince 2023
-
Frank Litvack · DirectorSince 2023
-
George W. Dunbar Jr. · DirectorSince 2023
-
Karimah Es Sabar · DirectorSince 2023
-
Linda Marban · Director · CHIEF EXECUTIVE OFFICERSince 2023
-
Louis Manzo · DirectorSince 2023
-
Mike Kelliher · DirectorSince 2023
-
Paul Gisbert Auwaerter · DirectorSince 2023
-
Philip J. Gotwals · DirectorSince 2023
Chief executives
Linda Marban
· CHIEF EXECUTIVE OFFICER
Dates unknown
Director election results
Annual meeting of June 4, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
68.6%
-
79.3%
-
81.0%
-
81.2%
-
81.5%
-
82.4%
-
82.8%
-
82.8%
Board connections
1 of this board's directors also sit on 1 other board.
- via Philip J. Gotwals
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $8,366,256
- 13 sales by 3 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 25, 2026 | Krasney Karen Officer (EVP, GENERAL COUNSEL) | Option exercise | +24,100 | $3.18 | $76,638 |
| Jun 25, 2026 | Bergmann Anthony Officer (CHIEF FINANCIAL OFFICER) | Option exercise | +24,100 | $3.18 | $76,638 |
| Jun 25, 2026 | Krasney Karen Officer (EVP, GENERAL COUNSEL) | Open-market sale | −24,100 | $30.38 | $732,158 |
| Jun 25, 2026 | Bergmann Anthony Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | −24,100 | $30.38 | $732,158 |
| Jun 24, 2026 | Krasney Karen Officer (EVP, GENERAL COUNSEL) | Option exercise | +400 | $3.18 | $1,272 |
| Jun 24, 2026 | Bergmann Anthony Officer (CHIEF FINANCIAL OFFICER) | Option exercise | +400 | $3.18 | $1,272 |
| Jun 24, 2026 | Krasney Karen Officer (EVP, GENERAL COUNSEL) | Open-market sale | −400 | $30.00 | $12,000 |
| Jun 24, 2026 | Bergmann Anthony Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | −400 | $30.00 | $12,000 |
| Jun 22, 2026 | Krasney Karen Officer (EVP, GENERAL COUNSEL) | Option exercise | +500 | $3.18 | $1,590 |
| Jun 22, 2026 | Bergmann Anthony Officer (CHIEF FINANCIAL OFFICER) | Option exercise | +500 | $3.18 | $1,590 |
| Jun 22, 2026 | Krasney Karen Officer (EVP, GENERAL COUNSEL) | Open-market sale | −500 | $30.00 | $15,000 |
| Jun 22, 2026 | Bergmann Anthony Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | −500 | $30.00 | $15,000 |
| May 18, 2026 | Bergmann Anthony Officer (CHIEF FINANCIAL OFFICER) | Option exercise | +3,000 | $1.39 | $4,170 |
| May 13, 2026 | Frank Litvack Director | Option exercise | +3,937 | $1.39 | $5,472 |
| May 1, 2026 | Krasney Karen Officer (EVP, GENERAL COUNSEL) | Option exercise | +25,000 | $3.18 | $79,500 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.